Adoptive cellular immunotherapy using autologous T lymphocytes genetically engineered to express chimeric antigen receptors that recognize tumor antigens and mediate cytotoxic activity.
Autologous T lymphocytes are genetically engineered to express a chimeric antigen receptor that binds specific tumor-associated antigens (MHC-independent), activating the T cells to proliferate, release cytotoxic molecules and cytokines, and selectively kill antigen-expressing cancer cells.
CD19-directed CAR T cells bind CD19 on target cells, become activated, and kill via perforin/granzyme-mediated cytolysis and death-receptor pathways (e.g., Fas–FasL), inducing apoptosis of CD19+ cells.
Adoptive cellular immunotherapy using autologous T lymphocytes genetically engineered to express chimeric antigen receptors that recognize tumor antigens and mediate cytotoxic activity.
Autologous T lymphocytes are genetically engineered to express a chimeric antigen receptor that binds specific tumor-associated antigens (MHC-independent), activating the T cells to proliferate, release cytotoxic molecules and cytokines, and selectively kill antigen-expressing cancer cells.
BCMA-targeted CAR T cells bind BCMA on tumor cells, become activated, and kill them via perforin/granzyme-mediated cytolysis and death-receptor signaling (e.g., Fas/FasL), with supportive cytokine-mediated apoptosis.
Polyclonal antibody that depletes T cells to reduce rejection and GVHD.
Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.
Anti-thymocyte globulin binds CD2 on T cells and induces complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting the target cells.
Polyclonal antibody that depletes T cells to reduce rejection and GVHD.
Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.
ATG binds CD3 epsilon on T cells and induces complement-dependent lysis and Fc receptor–mediated ADCC/phagocytosis, depleting the target cells.
Polyclonal antibody that depletes T cells to reduce rejection and GVHD.
Polyclonal anti–T-cell IgG that binds multiple T-cell surface antigens and depletes T cells via complement-dependent lysis and Fc-mediated ADCC/phagocytosis, producing immunosuppression to reduce rejection and GVHD.
Polyclonal IgG binds CD3δ on T cells and triggers complement-dependent lysis and Fc-mediated ADCC/phagocytosis, depleting those cells.